Cost Of Providing CAR-T Therapies Could Derail Reimbursement In England
Executive Summary
Gilead claims that the mechanism used to work out the cost for the National Health Service in England of delivering CAR-T therapies to patients could threaten access to these medicines.
You may also be interested in...
Servier: Precision Approach To Immunotherapy Will Define New Oncology Era
Two oncology chiefs from the French firm talked to Scrip about how its pipeline echoes the emerging intersection between precision medicine and immuno-oncology and how biology is taking precedence over technology in cancer R&D.
UK Industry Urges Government To Drop Statutory Pricing Scheme Rate Hike
The ABPI, which represents the R&D-based pharmaceutical industry in the UK, says the proposed increase in the statutory scheme rebate sends "the worst possible signal" to global investors and boardrooms.
Proposals On EU-Wide Joint Clinical Assessments Fall Short, Warn German Industry Groups
The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.